Biomarker Collaboration and Licensing Deals 2016-2024


Biomarker Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2024

Publication date
May 2024
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

Biomarker Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the biomarker deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of biomarker deals from 2016 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter biomarker deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 509 biomarker deals announced since 2016 including financial terms where available including links to online deal records of actual biomarker partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of biomarker dealmaking. 

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in biomarker dealmaking since 2016.

Chapter 3 provides an overview of the leading biomarker deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in biomarker dealmaking with a brief summary followed by a comprehensive listing of biomarker deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of biomarker deals signed and announced since Jan 2016, where a contract document is available in the public domain. 

Chapter 6 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since Jan 2016. The chapter is organized by specific biomarker technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in biomarker deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Biomarker Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse biomarker collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Report scope

Biomarker Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of biomarker trends and structure of deals entered into by leading biopharma companies worldwide.

Biomarker Collaboration and Licensing Deals includes:
•    Trends in biomarker dealmaking in the biopharma industry
•    Directory of biomarker deal records covering pharmaceutical and biotechnology
•    The leading biomarker deals by value
•    Most active biomarker licensing dealmakers

Biomarker Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

•    What are the precise rights granted or optioned?
•    What is actually granted by the agreement to the partner company?
•    What exclusivity is granted?
•    What is the payment structure for the deal?
•    How are sales and payments audited?
•    What is the deal term?
•    How are the key terms of the agreement defined?
•    How are IPRs handled and owned?
•    Who is responsible for commercialization?
•    Who is responsible for development, supply, and manufacture?
•    How is confidentiality and publication managed?
•    How are disputes to be resolved?
•    Under what conditions can the deal be terminated?
•    What happens when there is a change of ownership?
•    What sublicensing and subcontracting provisions have been agreed?
•    Which boilerplate clauses does the company insist upon?
•    Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
•    Which jurisdiction does the company insist upon for agreement law?

Biomarker Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse biomarker collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in biomarker dealmaking
2.1. Introduction
2.2. Biomarker deals over the years
2.3. Most active biomarker dealmakers
2.4. Biomarker deals by deal type
2.5. Biomarker deals by therapy area
2.6. Biomarker deals by industry sector
2.7. Deal terms for biomarker deals
2.7.1 Biomarker deals headline values
2.7.2 Biomarker deal upfront payments
2.7.3 Biomarker deal milestone payments
2.7.4 Biomarker royalty rates

Chapter 3 – Leading biomarker deals
3.1. Introduction
3.2. Top biomarker deals by value

Chapter 4 – Most active biomarker dealmakers
4.1. Introduction
4.2. Most active biomarker dealmakers
4.3. Most active biomarker deals company profiles

Chapter 5 – Biomarker contracts dealmaking directory
5.1. Introduction
5.2. Biomarker contracts dealmaking directory

Chapter 6 – Biomarker dealmaking by technology type

Deal directory

Deal directory – Biomarker deals by company A-Z
Deal directory – Biomarker deals by deal type
Deal directory – Biomarker deals by therapy area

Deal type definitions

About Biopharma Research Ltd 
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Biomarker deals since 2016
Figure 2: Active biomarker dealmaking activity – 2016 - 2024
Figure 3: Biomarker deals by deal type since 2016
Figure 4: Biomarker deals by therapy area since 2016
Figure 5: Biomarker deals by industry sector since 2016
Figure 6: Biomarker deals with a headline value
Figure 7: Biomarker deals with an upfront value
Figure 8: Biomarker deals with a milestone value
Figure 9: Biomarker deals with a royalty rate value
Figure 10: Top biomarker deals by value since 2016
Figure 11: Most active biomarker dealmakers 2016 - 2024
Figure 12: Biomarker deals by technology type since 2016

Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted PDF)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

4D Path, 23andMe, A*STAR Agency for Science, Technology and Research, A*STAR Bioprocessing Technology Institute, A*STAR Singapore Immunology Network, A2 Biotherapeutics, Abbott Laboratories, Abbvie, AbFero Pharmaceuticals, Academic Medical Center, AC Immune, Aclipse Therapeutics, Adaptive Biotechnologies, ADC Therapeutics, Addario Lung Cancer Medical Institute, Adial Pharmaceuticals, Adiso Therapeutics, Adlai Nortye, Aelan Cell Technologies, Age Labs, AHN Autoimmunity Institute, AIkido Pharma, Akoya Biosciences, Alamar Biosciences, Alberta Health Services, Albert Einstein College of Medicine, Alcedis, Alchemab, Alector, Allegheny General Hospital, Alligator Bioscience, Allumiqs, Almac Diagnostics, Almac Group, Alnylam Pharmaceuticals, Alzheimer's Drug Discovery Foundation, Ambry Genetics, American Association of Neuromuscular & Electrodiagnostic Medicine, Amerimmune, Amgen, Amoy Diagnostics, AMRA, AMRA Medical, Amydis, Angers University, Applied DNA Sciences, Arbor Biosciences, Arbor Biotechnologies, ArcherDX, Arcis Biotechnology, Arcus Biosciences, Arena Pharmaceuticals, AriBio, AroCell, Artialis, Aslan Pharma, Assistance Publique-Hôpitaux de Paris, Asterand Bioscience, Asthma UK, AstraZeneca, ATAI Life Sciences, Atara Biotherapeutics, AUM Biosciences, Aural Analytics, Avera Heart Hospital of South Dakota, Avidity Biosciences, AXIM Biotechnologies, AyoxxA Biosystems, Babraham Institute, Banyan Biomarkers, Battelle, Baxter International, Bayer, Baylor Scott and White Research Institute, Beacon Biosignals, Beckman Coulter, BenevolentAI, Berg, Beth Israel Deaconess Medical Center, Big Eye Diagnostics, Bill and Melinda Gates Foundation, Bio-Rad Laboratories, Bio-Techne, BioAge Labs, BioArctic AB, Biocartis, Biocept, BioCheetah, Biodesix, Biogen, Biogenysis, Biognosys, BioLum Sciences, Biomarker Collaborative, BioMarker Strategies, Biomedical Advanced Research and Development Authority, bioMerieux, BiomX, Bionomics, Biosearch Technologies, Biothera Pharmaceuticals, Blackfynn, BlackThorn Therapeutics, Blinktbi, Blu Biotech, BluePen Biomarkers, Blueprint Medicines, Boehringer Ingelheim, Bonnie J. Addario Lung Cancer Foundation, BostonGene, Brain Biomarker Solutions in Gothenburg, BRAINBox Solutions, BrainScope, Breath Diagnostics, Brigham and Women's Hospital, Bristol-Myers Squibb, Broad Institute, Buck Institute for Age Research, Burning Rock, C4X Discovery, Cambridge Epigenetix, Cambridge Quantum Computing, Canary Speech, Cancer Genetics, Cancer Research Horizons, Cancer Research Institute, Cantabio Pharmaceuticals, Caprion Biosciences, Caraway Therapeutics, Carina Biotech, Caris Life Sciences, Carmentix, Case Western Reserve University, CASI Pharmaceuticals, CBD Solutions, Cedars-Sinai Medical Center, Celgene, Cellaria Biosciences, Cellgen Diagnostics, Cellkey, Celmatix, Celsius Therapeutics, Centre Leon Berard, Certis, Cerveau Technologies, Chembio Diagnostics, Children's Hospital Boston, Children's Research Institute, Christian Doppler Research Association, ChromaCode, Chugai Pharmaceutical, Cicero Diagnostics, Circular Genomics, City of Hope, CK Life Sciences, ClearLight Diagnostics, Cleveland Clinic, CND Life Sciences, Cogia Biotech, Cognition Therapeutics, CogState, Cohen Veterans Bioscience, Columbia University, Complete Genomics, Concr, COPD Foundation, CoreBiome, Cornell University, Covance, Critical Diagnostics, Crohn's and Colitis Foundation of America, Crossbeta Biosciences, Crown Bioscience, Cryostem, Curetis, Curis, Cyclerion Therapeutics, CYduct Diagnostics, CYTOVIA Therapeutics, Dana-Farber Cancer Institute, Danish Cancer Society Research Center, Danish Center for Strategic Research into Type 2 Diabetes, DarwinHealth, DataRobot, Deargen, Debiopharm, Decode Health, Deep Longevity, Defense Advanced Research Projects Agency, Definiens, Delfi Diagnostics, Department of Veterans Affairs, DestiNA Genomics, DiamiR, Discovery Life Sciences, Divergence Neuro Technologies, DNAnexus, Duchenne UK, Duke University, Duke University Medical Center, DxVx, e-NIOS, Eisai, Eli Lilly, Elo Life Systems, Elysium Health, EMD Serono, ENDRA Life Sciences, Enigma Biomedical, Enterome Bioscience, Entheon Biomedical, Epicore Biosystems, Epic Sciences, Epinomics, Erasmus University Medical Center, ErVimmune, Ethos Research & Development, Eureka Eurostars, Eurofins Scientific, European Commission, European Organization for Research and Treatment of Cancer, Evogen, Evotec, Exagen Diagnostics, Excelra, Exosome Diagnostics, Exosome Sciences, Expesicor, Feinstein Institute for Medical Research, Fibrogen, Fight Colorectal Cancer, Firefly Neuroscience, Flagship Biosciences, Fluidigm, Food Allergy Research & Education, Food and Drug Administration (FDA), Fortis Therapeutics, Foundation for the National Institutes of Health (FNIH), Foundation Medicine, Fox Chase Cancer Center, FOXO Technologies, Fred Hutchinson Cancer Research Center, Freenome, Friends of Cancer Research, Frontage Laboratories, FSHD Global Research Foundation, Fudan University, Fujirebio Diagnostics, Fulgent Genetics, Fundacion Progreso y Salud, G1 Therapeutics, G42 Healthcare, Galmed Pharmaceuticals, GATC Health, Gate Neurosciences, GC Pharma, GeneCentric Therapeutics, GeneDX, Genentech, Geneoscopy, General Inception, Genialis, Geninus, Genomic Testing Cooperative, Genosity, Genprex, GenScript Biotech, Gentris, Genuity Science, Georgetown University, Georgetown University Hospital, George Washington University, GI Innovation, Gilead Sciences, Global Cancer Technology, GlycoT Therapeutics, Glympse Bio, Google, Government of South Korea, Grail, Gritstone Bio, Guardant Health, Gusto Global, H3 Biomedicine, Hadassah Medical Center, Halia Therapeutics, HalioDx, Health Sciences Research Institute Germans Trias i Pujol Foundation, Heat Biologics, Hebrew University of Jerusalem, Henan Cancer Hospital, Hengenix Biotech, Hennepin County Medical Center, Henry Ford Health System, Henry M. Jackson Foundation, Hepion Pharmaceuticals, Hoag Memorial Hospital Presbyterian, Horizon Discovery, Hoth Therapeutics, HP, HTG Molecular Diagnostics, Hummingbird Bioscience, Hummingbird Diagnostics, Hurdle, Icahn School of Medicine at Mount Sinai, Icometrix, IDEAYA Biosciences, Ikena Oncology, Illumina, Image Analysis, ImaginAb, Imanova, Imaware, Imeka, IMIDomics, Immodulon Therapeutics, ImmunArray, Immunexpress, Immunovia, IMPACT Therapeutics, Imperial College London, Imugene, IncellDx, Indica Labs, Indivumed, InfYnity Biomarkers, INmune Bio, InnoBation, Innodem Neurosciences, Innoplexus, Innovate UK, Inova Diagnostics, Inserm, Institut Curie, Institute for Systems Biology, Institut Gustave Roussy, Instituto Valenciano De Oncologia, Integrated Biobank of Luxembourg, Intermountain Healthcare, InterVenn, Invectys, Inventiva, inVentiv Health, inviCRO, Invitae, InVivoScribe, IO Biotech, iPrime Therapeutics, iProgen Biotech, Isogenica, IsoPlexis, iThera Medical, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Jefferson Healthcare, Johns Hopkins University, Johnson & Johnson Innovation, Jounce Therapeutics, JSR Life Sciences, Jubilant Therapeutics, Juventas Therapeutics, JW Biotechnology, K2bio, Kayagene, Keck Graduate Institute of Applied Life Sciences, Keen Eye, Keio Gijuku University, KeyWise, Khalpey AI Lab, Kineta, Kings College London, Koye Pharmaceuticals, Kymab, Kymera Therapeutics, Kyverna Therapeutics, Laboratory Corporation of America, Lantern Pharma, Lantheus Holding, Latvian Institute of Organic Synthesis, Lawson Health Research Institute, LEO Pharma, Les Laboratoires Servier, LEXEO Therapeutics, Lexogen, LifeOmic, Lipidomics Consulting, Liquid Biosciences, Lonza, Lucid Diagnostics, Lunaphore, Lunit, Lupus Research Alliance, Maccabi Healthcare Services, Mainz Biomed, Mannin Research, Massachusetts General Hospital, Massachusetts Institute of Technology, Mater Research, Mayo Clinic, MBio Diagnostics, MC10, McMaster University, MD Anderson Cancer Center, MD Biosciences, MEDIAN Technologies, Medical College of Georgia, Medical Research Council, Medical University of Graz, Medicinal Genomics, Medicines Discovery Catapult, MediciNova, MEDiC Life Sciences, Memorial Sloan Kettering Cancer Center, Mendel Health, Merck and Co, Merck KGaA, Metabolon, Michael J Fox Foundation, Microba Life Sciences, Microbiotica, Micronoma, Microsoft, Mindstrong Health, miRecule, Mirnax Biosens, MiRXES, Mission Bio, Mitsubishi Tanabe Pharma, MOBILion Systems, Moderna, MolecularMD, Mologen, Montreal Heart Institute, mProbe Laboratories, Muscular Dystrophy Association, MyBiotics Pharma, My Care Express Merrillville, MyCartis, MYND Life Sciences, Myriad RBM, NanoMab Technology, Nanostics Precision Health, NanoString Technologies, NanoView Biosciences, Nashville Biosciences, National Cancer Center, National Cancer Center of Japan, National Cancer Institute, National Center for Tumor Diseases, National Comprehensive Cancer Network (NCCN), National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of General Medical Sciences, National Institute of Mental Health, National Institute on Aging, National Institutes of Health, National Science Foundation, Naval Medical Research Center, Navidea Biopharmaceuticals, Navigate BioPharma Services, Navinci Diagnostics, Nektar Therapeutics, NeoDynamics, Neogenomics, Neoteryx, Nepean Blue Mountains Local Health District’s Nepean Hospital, NervGen Pharma, NetraMark, NeuraLight, NeurExo Sciences, NeuroGenesis, NeuroLex Laboratories, Neuron23, NeuroPointDX, NeuroSense Therapeutics, NeuroTrauma, New Horizon Health, Newomics, New York Blood Center, Nightingale Health, Nippon Kayaku, NMI TT Pharmaservices, Nordic Bioscience, Northwestern University, Novartis, Novogene, Nrgene, Nucleai, Nucleix, NuGen Technologies, Numares, NuMedii, Nurosene, NxGEN MDx, NX Prenatal, NYU Grossman School of Medicine for Preclinical and Clinical Research, Ocean Genomics, Offspring Biosciences, Ohio State University, Oklahoma Medical Research Foundation, Olaris, Oligomerix, Olink Proteomics, Oncoceutics, OncoCyte, OncoGenesis, OncoHost, Oncologie, Oncology Venture, OncoMed Pharmaceuticals, Onconova Therapeutics, OncoSec Medical, OneThree Biotech, Ono Pharmaceutical, Ontario Institute for Cancer Research, Optina Diagnostics, Ordaos Bio, Oregon Health Sciences University, OSE Immunotherapeutics, Oslo University Hospital, Ovid Therapeutics, Owlstone Medical, Oxford Biodynamics, Ozette Technologies, Paige, Pangea Biomed, Parent Project Muscular Dystrophy, PathAI, PAVmed, PEAR Therapeutics, Pennsylvania State University, Persephone Biosciences, Personal Genome Diagnostics, Personalis, Pfizer, Pharus Diagnostics, PhysIQ, PlaqueTec, Plus Therapeutics, PPD, Precision for Medicine, PrecisionLife, PredictImmune, Prelude Therapeutics, Prenosis, Prescient Medical, Prevacus, Probiodrug, Progentec Diagnostics, PrognomIQ, Prognos, Prolytix, ProPath, Protagen, Protagonist Therapeutics, ProteoMediX, Provista Diagnostics, Psomagen, Pulmonary Fibrosis Foundation (PFF), Q BioMed, Qiagen, Quadrant Biosciences, Quanterix, Quantum Leap Health Care Collaborative, Queen Mary University of London, Quest Diagnostics, Quotient, RareCyte, RCK, Readout Health, Redx Pharma, Regulus Therapeutics, Related Sciences, Research Council of Norway, Reveal Biosciences, Reveal Genomics, Revitalist Lifestyle and Wellness, Revive Therapeutics, Rheos Medicines, Rhythm Pharmaceuticals, RiboMed, RIKEN Research Institute, Roche, Roche Diagnostics, Rockefeller University, Rockley Photonics, Rosetta Genomics, Royal College of Surgeons (Ireland), Royal Philips Electronics, Rush University Medical Center, Saga University, Saladax Biomedical, Sanford Burnham Institute, Sanofi, Sanofi-Pasteur, Sano Genetics, Scailyte, Secarna Pharmaceuticals, Second Genome, Seneca Therapeutics, Sengenics, Sentinel Diagnostics, Sentinel Oncology, Serosep, Seven Bridges Genomics, Shanghai Institutes of Preventative Medicine, Sheba Medical Center, Sheffield Institute for Translational Neuroscience, Shire Human Genetic Therapies, Shuttle Pharmaceuticals, Siemens, Siemens Healthineers, SimBioSys, Singlera Genomics, Singulex, Sirona Dx, SkylineDX, SomaLogic, Sonde Health, Sony DADC, Sookmyung Women's University, SOPHiA Genetics, Soricimed Biopharma, Spark Biomedical, Spectrum Solutions, SpeeDx, Sphingotec, SQI Diagnostics, SquareOne Wellness, SRI International, Stalicla, Stallergenes Greer, Standard BioTools, Stanford University, Stanford University School of Medicine, Stella Diagnostics, Step Pharma, Strata Oncology, STRATIFYER Molecular Pathology, SUNY Upstate Medical University, Surrey Cancer Research Institute, Swiss Institute of Bioinformatics (SIB), Syapse, SynGAP Research Fund, TaiRx, Takeda Pharmaceutical, Tampere University Hospital, Taysha Gene Therapies, Tempus, Tennessee Oncology, Terran Biosciences, The Cure Parkinson's Trust, The Cyprus Institute of Neurology and Genetics, The Parker Institute For Cancer Immunotherapy, Theralink Technologies, Thermo Fisher Scientific, The Technical University Of Munich, Thomas Jefferson University, Tocagen, Todos Medical, TONIX Pharmaceuticals, Tor Vergata University Hospital, Total Brain, Translational Genomics Research Institute, TrovaGene, Tymora Analytical Operations, Ultivue, Umoja Biopharma, University Ann & Robert H. Lurie Children’s Hospital, University Hospitals Case Medical Center, University of Alabama at Birmingham, University of California, San Diego, University of California Berkeley, University of California Los Angeles, University of California San Francisco, University of Chicago, University of Cincinnati, University of Heidelberg, University of Houston, University of Leeds, University of Ljubljana, University of Manchester, University of Maryland, University of Maryland Baltimore, University of Melbourne, University of Michigan, University of Minnesota, University of Nebraska, University of New South Wales, University of North Carolina, University of Oxford, University of Pennsylvania, University of Rochester, University of Sheffield, University of Surrey, University of Texas Health Science Center at Houston, University of Washington, University of Wisconsin Carbone Cancer Center (UWCCC), University of Wollongong, US Department of Commerce, Vaccinex, Vall d’Hebron Research Institute, Vanderbilt University, Vector Laboratories, Ventana Medical Systems, Veravas, Verily, VeriSIM Life, Versea Ophthalmics, VGI Health Technology, VIB, ViewMind, Virginia Commonwealth University, Visiopharm, Vivante Health, Vocalis Health, VolitionRX, Vyant Bio, Waters Corporation, Wearifi, Wellmarker Bio, WIN Consortium, WinterLight Labs, WuXi NextCODE Genomics, XtalPi, Yale School of Medicine, Yale University, Ymir Genomics

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.

We found other products you might like!